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INTRODUCTION 
 
 
1.1 Cholesterol as Structural and Regulatory Component of Brain Cells and 
Membranes 
Cholesterol represents an important component of eukaryotic cell membranes. 
Cholesterol modulates membrane fluidity and organisation [1] where it can alter 
signalling functions, membrane protein organisation and lipid raft structure [2,3]. 
Cholesterol is also involved in vitamin D production and synthesis of bile acids 
and steroid hormones [4]. 
Cholesterol is not only an essential structural component for cellular membrane, 
a precursor of steroid hormones and bile acid synthesis, but also a required 
component for myelin, synapse and dendrite formation [5,6] and axonal guidance [7]. 
Brain is the most cholesterol-rich organ containing about 20% of the whole body’s 
cholesterol [8]. Brain lipids consist of glycerophospholipids, sphingolipids, and 
cholesterol,  they are in roughly equimolar proportions. 
The major sterol in the adult brain is unesterified cholesterol; larger portion of this 
fraction (about 70%–80%) is in myelin sheaths formed by oligodendrocytes to 
insulate axons; the remaining portion is made up by plasma membranes of astrocytes 
and neurons to maintain their morphology [9]. 
Cholesterol can also influence cell function through oxysterols, its biologically 
active side-chain oxidized products [10-12]. 
Cholesterol depletion in neurons impairs synaptic vesicle exocytosis, neuronal 
activity and neurotransmission and it leads to dendritic spine and synapse 
degeneration [13-14]. 
Cholesterol is essential for neuronal physiology, both during development and in 
the adult stage. 
Cholesterol has the common structure of a sterol, containing a carbon 3 hydroxyl 
group and a tetracyclic steroid ring.  Specifically, cholesterol contains a 3β hydroxyl 
group and an isooctyl hydrocarbon tail (Figure 1). The opposing polarity of the 
hydroxyl group and hydrocarbon structure of the remaining molecule gives to 
cholesterol its amphipathic nature. 
 
1.2 Cholesterol Byosinthesis 
       All nucleated cells can synthetize cholesterol [15]. 
       Synthesis of cholesterol, like that of most biological lipids, begins from the two-
carbon acetate group of acetyl-CoA. 
Acetyl-CoA units are converted to mevalonate by multiple reactions that begin 
with the formation of  3-hydroxyl-3-methylglutaryl-CoA (HMG-CoA) by the action 
of HMG-CoA synthase encoded by the HMGCS1 gene. 
HMG-CoA is then converted in mevalonate by HMG-CoA reductase (HMG-
CoAR). This reaction is the rate limiting step of cholesterol byosinthesis, and this 
enzyme is subject to complex regulatory controls as discussed below. Mevalonate is 
then activated by two successive phosphorylations and sequentially converted into 
isorene based molecule isopentenyl pyrophosphate (IPP); IPP is converted into 
squalene that undergoes a two-step cyclization to yield lanosterol. Through  further 19 
additional reactions, lanosterol is converted into cholesterol (Figure 2). 
These 19-reaction steps are catalyzed by nine different enzymes that are 
localized either in  endoplasmic reticulum (ER) or in peroxisomes. 
Less than an half of the cholesterol in the body derives from de novo 
biosynthesis and the remaining is provided by the diet.  Dietary cholesterol is 
absorbed by small intestine, loaded on lipoproteins and delivered to the liver. De novo 
synthesis or uptake from lipoproteins provides cellular cholesterol needs. 
Cholesterol sinthetized by the liver, as well as any dietary cholesterol in the liver 
that exceeds hepatic needs, is transported in the serum predominantly as cholesteryl 
esters associated with lipoproteins (LDL) to peripheral tissues. The free cholesterol 
within the cell has the following fates: incorporated into cell membranes; metabolized 
to steroid hormones of adrenal cortex and gonads; esterified with saturated fatty acids 
and stored in cells. 
Cholesterol found in plasma membranes can be extracted by HDLs, esterified by 
the HDL-associated enzyme lecithin-cholesterol acyltransferase (LCAT), transferred 
to VLDLs and LDLs and finally re-transferred to the liver [16]. 
Average diet contains about 300 mg of cholesterol per day. Body synthesizes 
about 700 mg /day. About 500 mg of cholesterol is excreted through the bile. Some 
part is reabsorbed from intestine, remaining portion is excreted in bile as free 
cholesterol or as bile salts as result of conversion to bile acids in the liver [17]. 
 
 
1.3 Cholesterol turnover 
Since an excess of free cholestrol is toxic, all body cells adopt several defensive 
strategies such as exporting it via lipoprotein, storing it in as esterified form or 
releasing it after oxidation into oxysterols [18]. Cholesterol and oxysterols are 
directly involved in a negative feedback mechanism of the enzyme regulation both at 
the protein and the transcriptional level [19]. 
The continual alteration of the intracellular sterol content occurs through the 
regulation of key sterol synthetic enzymes as well as by altering the levels of cell-
surface LDL-receptors. As cells need more sterol they will increase synthesis and 
uptake, conversely when the need is lower synthesis and uptake decreases. 
Regulation of these events is brought about primarily by degradation and by 
sterol-regulated transcription of HMGCoAR [20]. Indeed, when cholesterol is in 
excess it induces a rapid degradation of HMGCoAR. In addition, the amount of 
mRNA for HMGCoAR is reduced as a result of decreased expression of the gene. 
Activation of transcriptional control occurs through the regulated cleavage of the 
membrane-bound transcription factor sterol regulated element binding proteins 
(SREPBs). This transcription factor regulates lipid homeotasis in cells by activation 
of more than 30 genes involved in the synthesis and uptake of cholesterol, fatty acids, 
triglycerides and phospholipids. 
SREPBs are expressed as inactive precursors (pSREPBs) integral to the ER 
membrane. When intracellular cholesterol levels are low, pSREPBs are translocated 
from the ER to the Golgi apparatus by an escort protein, SREPB cleavage-activating 
proten (SCAP), where they are cleaved into active not membrane-bound trascription 
factors. These shorter mature SREPBs (mSREPBs) enter in the nucleus and modulate 
transcription of genes containing an octamer sequence in the promoter region, termed 
the sterol regulatory element (SRE-1).  When intracellular cholesterol levels are in 
excess, SCAP, which has a cholesterol-sensing domain, binds insulin induced gene 
(Insig) and the Insig-SCAP-pSREPB is retained in the ER reducing cholesterol 
synthesis [21,22]. 
High concentration of cholesterol activates the expression of SREPB gene via 
the action of Liver X receptors (LxRs). The LxRs are members of the steroid/thyroid 
hormone superfamily of cytosolic ligand binding receptors that migrate to the nucleus 
upon ligand binding end regulate gene expression by binding to specific target 
sequences. There are two forms of the LxRs: LxRα (NR1H3) and LxRβ (NR1H2). 
LXRs heterodimerize with retinoid X receptors (RxRs) and are activated by specific 
cholesterol derivatives that function as endogenous ligands [23-27]. 
Well known set of ligands are oxysterols, oxidized metabolites of cholesterol 
that are present in very low concentrations in mammalian systems and are always 
accompanied by high excess of cholesterol ( for instance, 27-hydroxycholesterol, 
22(R)-hydroxycholesterol (22-HC) and 24(S)-hydroxycholesterol (24(S)-HC) [28]. 
More recently, cholestenoic acids have also been identified as endogenous LXR 
ligands [29], suggesting novel functions for LXR ligands in the developing and the 
adult brain. 
The best known functions of Lxrs are the regulation of lipid metabolism and 
homeostasis [27, 30-32], increases of cholesterol efflux from cells [27,33,34], and 
protection from cholesterol overload and toxicity [33,35]. Accordingly, direct LXR 
target genes encode for ATP-binding cassette (ABC) transporters (ABCA1 and 
ABCG1/5/8), apolipoproteins (E, C1, C2, C4, and D), cytochrome P450 7A1 (in 
rodents but not in humans), and enzymes involved in lipogenesis such as SREBP1c, 
FAS, and stearoyl-CoA desaturase-1. In the last decade, additional functions of Lxrs 
and their ligands have been described. These include the regulation of inflammation 
[36] and different aspects of the immune response [37], including the regulation of 
the balance between cell survival and death in macrophages [38].   
 
1.4 Brain cholesterol metabolism 
The amount of sterol in brain ranges from15 to 20 mg per gr in many species as 
unesterified cholesterol [9]; however, small amount of desmosterol and cholesteryl 
ester are also present. 
Brain cholesterol is primarily supplied by de novo synthesis due to the 
prevention of lipoproteins uptake from the circulation by blood brain barrier (BBB) 
[8]. 
Brain cholesterol synthesis follows the same pathway present in peripheral 
tissues as described before. 
The majority of brain cholesterol accumulates between the perinatal period and 
adolescence when neurons are encircled by myelin. This de novo synthesis is 
adequate accounting for the cholesterol accumulation rate during early development, 
when myelin production takes place  by oligodendrocytes [9]. The highest cholesterol 
synthesis rate in human, in fact, takes place when the peak of myelination process 
occurs, the myelination process is delayed when cholesterol synthesis is deficient 
[39]. When the process of brain maturation and myelin formation is concluded in the 
adulthood, the neurons down-regulate their cholesterol synthesis and rely on delivery 
of cholesterol from astrocytes that differentiate post-natally and release cholesterol 
rich lipoproteins (the “outsourcing” hypothesis of brain cholesterol metabolism) [40-
42]. There may be several reasons for this process. The high energy cost and the need 
for a large number of enzymes in different cellular compartments may explain why 
neurons, whose primary function is electrical synaptic transmission, abandon 
cholesterol synthesis after foetal development. The elongated shape of the neuron 
may also hinder transport of cholesterol from the site of its  production in the cell 
body to the site where it is needed. 
Astrocytes release cholesterol on HDL-like particles with ApoE as 
apolipoprotein via ABC-A1 and ABC-G1 transporters [43,44]. The ApoE lipoproteins 
are internalized into neurons by the LDL-receptor (LDL-R) and the LDL-related 
protein (LRP), but also by to some extent via VLDL receptor, ApoE receptor 2, and 
megalin. The ApoE-receptor–cholesterol complexes are delivered to the late 
endosomes/lysosomes where acid lipase hydrolyzes the cholesterol esters within the 
lipoprotein complexes, with the intracellular release of free cholesterol. This 
unesterified cholesterol exits the late endosomes/lysosomes via a Niemann–Pick type 
C (NPC) 1 and NPC 2 protein-dependent mechanism and it is distributed to the 
plasma membrane as well as to the ER; as a result  unesterified cholesterol acts as a 
negative feedback sensor for the cholesterol homeostasis genes such as HMGCoAR 
and LDL-R. The cholesterol in excess, on the other hand, is esterified in the ER by 
acyl-CoA-cholesterol acyltransferase (ACAT) and stored in cytoplasmic lipid droplets 
as a reserve pool. This intracellular pool of cholesterol is necessary for  synaptic and 
dendritic formation and in membrane remodeling. 
When cholesterol synthesis rate exceeds its acquisition rate in the brain, the 
excess of cholesterol must still be removed from the brain; but the BBB is 
impermeable to cholesterol, therefore simple transfer of cholesterol into blood stream 
does not occur. It has been suggested that cholesterol can move into the cerebrospinal 
fluid (CSF) as ApoE particles and then into the plasma. However, this accounts only 
for a small amount of cholesterol removed to the periphery, indicating other 
mechanisms must be at play. 
Conversion to oxysterol is the major excretion way in the brain. The addition of 
a hydroxyl group to the alkyl chain of the cholesterol molecule significantly increases 
cell membrane permeability; side chain oxidised sterols move across membranes 
approximately 1500 times faster than cholesterol [45]. A cytochrome P-450, 
cholesterol 24- hydroxylase (CYP46A1), expressed primarily in neurons, catalyses 
this reaction [46]. 
It is well established that neuronal cells regulate their cholesterol content by an 
exquisite feedback mechanism that balances biosynthesis, import and excretion. Cells 
sense their level of cholesterol by membrane-bound transcription factors known as 
sterol regulatory element-binding proteins (SREBPs) that regulate the transcription of 
genes encoding enzymes of cholesterol and fatty acid biosynthesis as well as 
lipoprotein receptors [47] to either increase cholesterol synthesis and uptake in sterol-
depleted cells or decrease cholesterol-synthesizing enzymes when sterols are 
overloaded in cells [48,49]. 
When cholesterol reaches the maximal safe level, oxysterols act as an 
endogenous ligand of the LXRs which increase the expression of cholesterol transport 
genes [50] including ABCA1 in both neuron and glia cell [51], apoE in astrocyte 
[40,52]; consequently cholesterol efflux is increased (Figure 3). 
 
 
 
1.5 Cholesterol and Neurodegenerative Disease 
Cholesterol is an essential molecule for cellular function; however, excess cholesterol 
circulating in the body can be harmful. It has been established that high levels of 
cholesterol in the blood contributes to a number of diseases, in particular 
atherosclerosis and cardiovascular disease [53]. The influence of altered cholesterol 
homeostasis in neurodegenerative diseases is, however, not well understood. 
Cholesterol levels have been reported to alter in vitro protein aggregation relevant to 
Parkinson Disease [54,55]. Several studies have also highlighted altered brain 
cholesterol levels in Alzheimer Disease (AD) [51,56,57], and may influence amyloid 
beta formation by altering the physical properties of cell membranes [58]. It is also 
hypothesised that cellular redistribution of cholesterol without changes in total 
cholesterol levels may play a role in AD [59].  
Parkinson's disease is a progressive neurodegenerative disorder characterized by the 
loss of dopaminergic neurons in the substantia nigra and the accumulation of α-
synuclein (Lewy bodies). Several interesting findings have shown the occurrence of 
equivalent Parkinsonian pathologies in cellular neuronal models, mediated 
by oxysterols or excess exposure to cholesterol. In this regard, oxysterols are 
particular in causing alpha-synuclein aggregation and destruction of dopamine 
containing neurons in in vitro models, which is linked to their direct influence on 
oxidative stress provoking potency. Inspite of the significant in vitro reports, which 
suggest the relativeness of cholesterol or oxysterol towards Parkinsonism, several 
prospective clinical reports provided a negative or no correlation [54]. Several in vivo 
studies have shown a relationship between the lipid profile, the use of drugs 
regulating cholesterol levels, and the development of Parkinson's disease. 
Several oxysterols are present in the brain and could play a role in the development of 
this disease, particularly in the accumulation of α-synuclein, and through various side 
effects, such as oxidation, inflammation, and cell death. Consequently, in Parkinson's 
disease, some oxysterols could contribute to the pathophysiology of the disease and 
constitute potential biomarkers or therapeutic targets [55].  
Alzheimer’s disease is a neurodegenerative disorder characterized by progressive and 
irreversible memory impairment and cognitive decline. The pathological hallmarks of 
AD are extracellular amyloid plaques of amyloid β (Aβ) peptide and intracellular 
neurofibrillary tangles. Cholesterol is found to be enriched 
in the brain plasma membranes of AD patients. The cholesterol level increases 
throughout the course of clinical disease, and more increase was observed when the 
disease progresses. In vitro study indicated that overload of cholesterol at plasma 
membrane in primary cultured neurons leads to an increase of Aβ production through 
increasing BACE1-mediated APP cleavage. APP intracellular domain (AICD) release 
increases during this process, which down-regulates low density lipoprotein-related 
protein 1 (LRP1) transcription that is responsible for exogenous cholesterol 
capture at the plasma membrane, this ultimately results in a decrease of cellular 
cholesterol levels[56, 57]. 
Due to conflicting reports of cholesterol levels in neurodegenerative brain tissue, 
the exact influence of altered cholesterol homeostasis in neurodegenerative diseases is 
currently unknown. 
 
 
1.6 Huntington's disease 
 
HD is an autosomal dominant, progressive, neurodegenerative disease 
characterised by the expansion of a trinucleotide repeat on the N-terminus of the 
huntingtin protein (HTT). The cytosine-adenine-guanine (CAG) repeat, coding for 
glutamine, is located on exon 1 of the HTT gene [60]. 
The exact role of the CAG mutation on the HTT protein in HD pathogenesis is 
still debated. It is not completely clear if mutant huntingtin (mHTT) has a toxic gain 
of function or if a loss of function is responsible for disease, or possibly a 
combination of both factors. The heterozygous disruption of the HTT gene does not 
cause a HD phenotype in human cases, suggesting that the loss of function in one 
allele is not entirely responsible for disease pathology [61]. Expression of normal 
length HTT can reduce the toxicity of mHTT in mice [62] and it suggests 
compensation for loss of function. Another debated hypothesis of mHTT toxicity 
involves protein aggregation. Aggregation of mHTT is a hallmark of HD; however, 
this may not be an accurate predictor of cell death. Aggregate formation is higher in 
cortical neurons, that are relatively spared compared to the selectively vulnerable 
striatal neurons that contain fewer aggregates [63]. In vitro studies investigating 
mHTT aggregation have also reported neuronal death without the formation of 
inclusions, and that cells forming inclusions had reduced risk of death [64]. In those 
studies cells forming inclusions had reduced levels of mHTT compared to cells 
without inclusions suggesting that inclusion formation may be protective. Although 
inclusions may not be directly linked to cell death, other lines of evidence suggest that 
proteasomal disruption in cells caused by mHTT aggregates may be neurotoxic [65]. 
Although huntingtin is ubiquitously expressed, the brain is primarily affected in 
HD, with the striatal medium spiny neurons and cortical neurons being particularly 
vulnerable [66]. 
Huntington’s disease shows a stable prevalence in most populations white of 
people of about 5–7 affected individuals per 100 000. 
Individuals with Huntington’s disease can become symptomatic at any time 
between the ages of 1 and 80 years; before then, they are healthy and have no 
detectable clinical abnormalities. This healthy period merges imperceptibly with a 
prediagnostic phase, when patients show subtle changes of personality, cognition, and 
motor control.  Diagnosis takes place when findings become sufficiently developed 
and specific. During the diagnostic phase  the affected individuals show distinct 
chorea, incoordination, motor impersistence, and slowed saccadic eye movements. 
Cognitive dysfunction in Huntington’s disease, often spares long-term memory but 
impairs executive functions, such as organising, planning, checking, or adapting 
alternatives, and delays the acquisition of new motor skills. Unlike cognition, 
psychiatric and behavioural symptoms arise with some frequency but do not show 
stepwise progression with disease severity. Depression is typical and suicide is 
estimated to be about five to ten times higher compared to general population [67]. 
As motor and cognitive deficit becomes severe, patients eventually die, usually 
from complications of falls, inanition, dysphagia, or aspiration. Typical latency from 
diagnosis to death is 20 years. 
 
 
 
1.7  Cholesterol Metabolism In Huntington Disease 
 
 
Molecular and biochemical studies in cellular and animal models have shown 
that cholesterol biosynthesis is altered  in HD [68]. 
Decreased amounts of 24S-OHC have been reported in transgenic and knock-in 
mouse model of HD [69].In this context, brain cholesterol metabolism in the YAC 
transgenic HD mice appeared to be related to the repeat length, since disease-related 
decline of brain lathosterol, cholesterol, and 24OHC content was found to be 
proportional to the length of the CAG repeat [70].. In addition, in a knock-in HD mice 
model, the heterozygous and homozygous animals had brain 24OHC reduced by 20% 
and 50%, respectively [71].. It seems likely from these studies that both the length of 
CAG repeat and the mtHtt  load have negative effects on brain cholesterol synthesis 
(reduced lathosterol), and cholesterol turnover (reduced 24-OHC).   
Similar observation has been reported in tissue and fluid samples from HD 
patients in whom the decrease of plasma 24-OHC associates to progression of disease 
proportionately to motor and neuropsychiatric dysfunction and MRI brain atrophy 
[72,73]. 
Further study focused on the relative importance of the brain-specific catabolite 
24OHC, as a marker of HD progression, being an index of whole-body cholesterol 
elimination [74]. This hypothesis is based on a significant reduction in levels of 
24OHC in plasma from HD patients.    
Efflux of 24OHC is regarded as the main mechanism through which the brain 
removes daily excesses of cholesterol. Therefore, plasma 24OHC levels may be index 
of brain cholesterol elimination (and indirectly of cholesterol biosynthesis). On this 
basis, reduced levels of 24 OHC is supposed to indicate that cholesterol catabolism is 
reduced in brain. 
The intriguing hypothesis that brain cholesterol abnormalities might contribute 
to HD  pathophysiology may be further supported by the fact that 24OHC decreases 
in parallel with the volume of the caudate, a brain region specially affected in HD. In 
addition, blood concentration of  lanosterol, lathosterol and 24OHC were significantly 
reduced in pre-manifest HD and HD patients. This suggests that whole-body 
cholesterol homeostasis is impaired also in humans at pre-symptomatic stages of HD 
[75]. 
Further potential mechanism underlying cholesterol alterations in HD is the 
reduced activity of Sterol regulatory element binding proteins (SREBPs) that regulate 
the genes transcription of  cholesterol biosynthetic pathway. SREBP activity was 
reduced in an inducible cell model of HD and in brain of HD mouse [76]. 
To elucidate new transcriptional pathways regulated by huntingtin, Futter et al. 
tested several brain expressed nuclear receptors (NRs) for their ability to interact with 
the N-terminal fragment of huntingtin (amino acids 1–588) with a normal (17Q) or 
expanded (138Q) polyglutamine repeat. They found that Liver X Receptors (LXR) 
bound to wild-type huntingtin via its ligand binding domain (LBD). Over-expression 
of huntingtin activates LXR mediated transcription and knockout of huntingtin 
decreases LXR mediated transcription. Furthermore, knockout of huntingtin 
decreases expression of  ATP binding cassette transporter A1 (ABCA1), a key 
downstream target gene regulated by LXR. An agonist of LXR partially rescues the 
phenotype observed in huntingtin deficient zebrafish [77]. 
These data suggest that huntingtin can regulate LXR mediated transcription and 
may play a general role as a cofactor of nuclear receptors. LXR transcriptional 
deficiency may contribute to the phenotypes of huntingtin defects in vivo. 
 
 
 
 
 
STUDY DESIGN 
 
 
2.1  Aims 
 
          The  mechanisms underlying cholesterol perturbations are still poor understood 
and their potential role in the pathogenesis of HD is not well ascertained. 
To our knowledge, no study have evaluated the cholestenoic acid profile of HD 
patients as well as  investigated the role of LXRs in the pathogenesis of HD. 
Aim of this study is to assess a potential association between nuclear 
transcription factors related to cholesterol metabolism such as LxRs and the 
cholesterol dysfunction in HD patients. Indeed, in order to confirm in humans the 
hypothesis that mutant Htt is less able to up-regulate Lxrα and LxRβ targeted-genes, 
we have evaluated gene expression of LxR α and β and LxR target genes (ABCA1, 
ApoE, SREPB, CYP7B1) in HD patients. Furthermore, motor and  cognitive markers 
of progression have been assessed and compared with LxRs levels, in order to find a 
correlation between levels of  LxRs and severity of  HD disease. 
 
 
2.2 Materials and Methods 
 
The study was performed in a cohort of 130 consecutive patients afferent to the 
HD Clinics at the Department of Neurosciences and Reproductive and 
Odontostomatologic Sciences, Federico II University, Naples. 
     Inclusion criteria oh HD patients were: age 18-60 years, manifest signs and 
symptoms of the disease and positive molecular test for the presence of a CAG triplet 
repeat expansion > 35 in the HD gene. 
Being aware that plasma levels of oxysterols might be influenced by factors as 
lipoproteins transport and liver clearance, we excluded participants with history of 
Diabetes, dyslipidemia, metabolic syndrome or other endocrine disorders, 
chronic/acute liver dysfunction and chronic systemic disease. Also, potential effects 
of lipid lowering therapies (such as cholestiramine and statin treatments or 
phytosterol intake) on oxysterols levels were taken into account and participants on 
statin therapy were excluded [78]. In order to eliminate the effects of an inadequate 
diet on  levels of cholesterol and its metabolites, alimentary diary and appropriate 
were supplied  the day before. Finally, blood samples were collected after an 
overnight fasting according to standard procedure for lipid study in clinical chemistry 
[79]. Patients confined to bed/wheelchair, unable to cooperate with the study and 
those on treatment with antipsychotic agents therapy were excluded. In the latter 
cases to exclude the influence of antipsychotic drugs on lipid metabolism [80,81].   
Clinical assessment of patients was performed using the Unified Huntington’s 
Disease Rating Scale (UHDRS) motor section and the Total Function Capacity (TFC) 
[82,83].  The following cognitive assessment were used: three Stroop tests (color, 
word, and interference) and the Symbol Digit Modalities Test (SDMT) [84]. 
The HD patients were stratified according to their neurological status using the 
median values of TFC and UHDRS-TMS as cut-off. 
All samples were collected between 9,00 and 10,00 a.m. in fasting conditions 
and a sample (5 ml) of peripheral blood was collected in Vacutainer tubes with EDTA 
and processed with FicollPaque (GE Healthcare) according to the manufacturer’s 
instructions. Peripheral blood mononuclear cells (PBMCs) isolated from blood 
samples were collected. 
Metabolic investigations included total cholesterol serum levels, triglyceride, 
High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), glucose levels. 
Analysis of LXRs, ABCA1, ApoE, CYP7B1 and SREPB mRNA extracted from 
peripheral total blood taken from HD patients and controls will be measured by 
Radioactive Semiquantitative Reverse Transcription-PCR (q-PCR) and conducted in 
the Laboratory of the Department of Neurosciences and Reproductive and 
Odontostomatologic Sciences, Federico II University, Naples. 
Total RNA will be extracted from whole blood using Paxgene blood RNA 
system  (Qiagen, Valencia, CA, USA) followed by purification with RNeasy Kit 
(Qiagen, Valencia, CA, USA) following the manufacturer's protocol. RNA 
concentration will be determined spectrophotometrically at 260 nm, and the 260/280 
nm ratio will determined the quality of the purification. In addition, RNA quality will 
be estimated by running RNA on agarose gel. Complementary DNA (cDNA) will be 
synthesized from equal amounts of total RNA and following the manufacturer’s 
protocol using SuperScript III reverse transcriptase (Invitrogen) with Random 
Hexamer primers. LXR, ABCA1, ApoE, CYP7B1 and SREPB mRNA will be 
measured by TaqMan real-time PCR assay, using glyceraldehyde-3-phosphate 
dehydrogenase (GAPD) as reference gene, and mRNA from HepG2 cells will be used 
as calibrator.                                                                                                                                                
For q-PCR, the 50 ng of cDNA will be added in reactions performed on an 
StepOnePlus Instrument  (Applied Biosystems, Foster City, CA, USA) using Taqman 
Universal PCR Master Mix (Applied Biosystem) and gene-specific primers. Primer 
for the selected gene (LXR, ABCA1, ApoE, CYP7B1 and SREPB) sequences  will be 
obtained from the literature and checked for their specificity through in silico PCR. 
Primers for all amplifications will be designed  using  Primer3 software. 
Amplifications will be done as technical triplicates in 96-well plates. The relative 
quantification value of each target gene will be analyzed using a comparative Ct 
method. The following formula will be used to calculate the relative amount of the 
transcript in the sample and normalized to the GAPD as endogenous reference: 
2−ΔΔCt, where ΔCt is the difference in Ct between the gene of interest and GAPD, 
and ΔΔCt for the sample=mean ΔCt of sample−mean ΔCt of the HepG2 cells. The 
gene expression will be interpreted as the increase or reduction in relative mRNA 
level after atorvastatin therapy. 
 
 
2.3  Statistical Analysis 
 
Patients and controls were compared using the two-tailed Student's t test for 
paired data. 
Comparison of basal data was performed using parametric or non  parametric 
tests for continuous variables and the chi-square or Fischer’s exact test as appropriate. 
Linear regression analysis was employed to assess correlation between number 
of CAG repeats, TFC and UHDRS-TMS values and gene expression levels. 
A p < 0.05 was considered statistically significant. 
 2.4  Results 
 
 From the initial cohort of among 130 consecutive patients afferent to the HD 
Clinics at the Department of Neurosciences and Reproductive and 
Odontostomatologic Sciences, Federico II University, Naples 14 HD patients met 
inclusion criteria and were compared with14 healthy subjects recruited among healthy 
volunteers matched to the patients according to age, sex and body mass index (BMI). 
      Demographic data of patients and controls are reported in Table 1. 
HD patients were divided in two subgroups according to the stage of the disease 
as determined by TCF and UHDRS. Cut-off value for stage I were TFC > 12 and 
UHDRS-TMS  ≤ 20 and for stage II it was TFC ≤ 12 and UHDRS-TMS > 20. 
HD patients did not differ from controls for levels of triglyceride, total and LDL 
cholesterol; they had significant lower HDL-cholesterol levels and a trend toward 
higher LDL-cholesterol levels (Table 2). 
As shown in Figure 4-9, the mRNAs of LXR α and β, ABCA1, ApoE, CYP7B1 
and SREPB showed similar levels in the HD and control group. 
No correlation was observed between the different values of the measured 
relative transcript levels in HD patients and CAG repeats and disease stage ( Figure 
10-15). 
 
 
 
2.5  Discussion 
Huntingtin may play a regulatory role in the normal cerebral and extra-cerebral 
biosynthesis of cholesterol which is modified in the presence of mutant HTT. 
Consistent findings about an impairment of synthesis, accumulation and turnover 
were reported in animal models of disease together with a reduction of the expression 
of key regulatory genes. The transcriptional dysregulation reduces the translocation of 
SREBP, the activation of LXR and LXR-dependent genes. The dysfunction of the 
cholesterol metabolism is not restricted to the Central Nervous System (CNS). 
Further support to the hypothesis that mutant huntingtin affects cholesterol levels 
comes from in vitro experiments showing that the biosynthesis of cholesterol and 
fatty acids is impaired in cells expressing disease-causing mutants of huntingtin. HD 
patients and HD mice show a progressive decrease of 24-OHC, which is a sign of 
neuronal cell loss. The decrease in this metabolite may further reduce cholesterol 
levels in the brain by impairing the activity of liver X receptors (LXRs), thus reducing 
expression of LXR-dependent transcripts like ABCA1 and ApoE and consequently 
the transport of cholesterol to neuronal cells. Evidence for a role of the LXR pathway 
in HD but not necessarily in ABCA1, ApoE and cholesterol levels in the brain comes 
from the observation that treatment with a LXR agonist partially reverts symptoms in 
a zebrafish model of HD. 
Although cellular and animal models make LxRs as strong factors for 
pathogenesys of HD, no definitive data are currently available on the involvement of 
LxRs in HD patients. 
To test whether mutant huntingtin induces gene expression changes in peripheral 
cells of HD patients we analyzed the RNA extracted from PBMC taken from control 
and HD patients. The results obtained reveal no differences of LxRs and LxRs target 
genes expression between HD patients and controls. 
These results are in contrast with those of other studies. Valenza et all. analyzed 
the RNA extracted from primary fibroblasts of controls and HD patients and 
demonstrated  that HD fibroblasts show a 35–45% reduction in HMGCoAR and 
Cyp51 mRNA levels. These data indicate that there is a significant reduction in the 
mRNAs for LxR target genes in HD subjects. 
The present study has some limitations such as the limited number of subjects. 
Further limitation is the lack of assessment of the possible pathogenetic significance 
of LxRs mRNA expression in fibroblast of HD patients. 
We cannot exclude a selection bias having excluded patients not treated with 
antipsycothics. This exclusion criteria allowed us to eliminate the effects of clozapine 
and olanzapine on weight, lipid abnormalities and diabetes through direct effects on 
insulin secretion and lipid biosynthesis and efflux genes associated with SREBP-
stimulated transcriptional changes [80,81]. As a conseguence our patients  were likely 
in not advances phase of HD disease and this could have influenced results. 
In conclusion, the present data suggest that there is no impairment of LxR gene 
expression in peripheral cells of HD patients. However we can not exclude a possible 
interplay between Htt and LxR as pathogenetic factor of HD. 
In any case the results of this study are hypothesis generating. In order to clarify  
the role of the above genes in alteration of cholesterol metabolism it would be 
interesting to analyze plasma levels of natural ligands of LXR levels such as 
oxysterols ( lanosterol, lathosterol, desmosterol, 24-HC, 27-HC) and colestenoic acids 
(3β-HCA, 3β,7α-diHCA, 3β,7β-diHCA) respect to controls and to extend the analysis 
to fibroblasts. 
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TABLE 1. Demographic data in HD patients and controlsand controls 
 
 
 PATIENTS CONTROLS p 
Number of patients 
(m/f) 
14(8/6) 14(8/6)  
Age, mean (years) 46,0 ± 10,8 45,6 ± 11,7  
Age et onset (years) 41,0 ± 10,9   
Disease duration, 
mean (years)   
5,09 ± 4,6   
CAG repeat mean  
allele 1 
18,3 ± 3,3   
CAG repeat mean  
allele 2 
45,8 ± 4,9   
UHDRS, mean 26,0 ± 15,3   
TFC, mean 8,2 ± 4,1   
BMI, mean 24,7 ± 4,3 24,6 ± 7,4 0,71 
 
 
 
 
 
 
 
 
TABLE 2. Biochemical data in HD patients and controls 
                                                                                                                                                                                                                                          
 PATIENTS CONTROLS p 
Total colesterol, mean 
(mg/dl) 
192,2 ± 47,2 187,7  ± 24,6 0,66 
LDL,  mean (mg/dl)   127,8 ± 43,9 108,6 ± 25,6 0,05 
HDL  mean (mg/dl)   47,4 ± 13,3 58,7 ± 7,7 0,0004 
Triglycerides,  mean 
(mg/dl)   
125,9 ± 95,2 100,1 ± 25,3 0,22 
Total Bilirubin, mean 
(mg/dl) 
0,5 ± 0,2 0,6 ± 0,1 0,56 
Creatinine, mean (mg/dl) 0,8 ± 0,3 0,7 ± 0,4 0,63 
Alanine Aminitransferase, 
mean (U/l) 
32 ± 12 29 ± 11 0,83 
Aspartate Aminitransferase 
mean (U/l) 
19 ± 4 20 ± 6 0,76 
 
 
 
 
 
 
 
 
FIGURE 1. Cholesterol chemical structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   FIGURE 2. Cholesterol byosinthesis 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 3. Brain cholesterol metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4. LxR β gene expression in HD patients and controls analysis 
byTaqman RT-PCR 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients Controls 
FIGURE 5. LxR α gene expression analysis in HD patients and controls 
byTaqman RT-PCR 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients Controls 
FIGURE 6. SREPB gene expression analysis in HD patients and controls 
byTaqman RT-PCR 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients Controls 
 FIGURE 7. ABCA1 gene expression analysis in HD patients and controls 
byTaqman RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients Controls 
 FIGURE 8. ApoE gene expression analysis in HD patients and controls 
byTaqman RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Controls Patients 
 FIGURE 9. CYP7B1 gene expression analysis in HD patients and controls 
byTaqman RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Patients Controls 
 FIGURE 10. Correlation LxR β expression CAG and disease severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 11. Correlation LxR α expression CAG and disease severity 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 FIGURE 12. Correlation SREPB expression CAG and disease severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 13. Correlation ABCA1 expression CAG and disease severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 14. Correlation ApoE expression CAG and disease severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 15. Correlation CYP7B1 expression CAG and disease severity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
